Dive Brief:
- Zimmer Biomet has filed for 510(k) clearance for an autonomous version of its Monogram orthopedic robot, a company spokesperson told MedTech Dive in an email.
- CEO Ivan Tornos said at an investor event this week that Zimmer made the filling on Monday and hopes to receive Food and Drug Administration clearance sometime next year.
- Tornos said he expects Monogram to be a “game-changing platform,” citing the robot’s safety, efficiency, ease of use and accuracy.
Dive Insight:
Zimmer acquired Monogram Technologies in 2025 for $177 million. At the time, the company had a semi-autonomous robot used in total knee replacement surgeries, and was working to develop a fully autonomous version that would be hands-free and activated using foot pedals.
Monogram’s robot differs from Zimmer’s existing orthopedic robot, Rosa, in that it can be used with CT imaging.
In a clinical trial of Monogram, Tornos said no safety events were reported. The robot helped with faster bone preparation and landmarking ahead of procedures.
At a Stifel conference on Sunday, two orthopedic surgeons discussed the new robot. They said it has potential for meaningful time savings, reduced instrument tray use and better accuracy, Stifel analyst Rick Wise wrote in a research note. The automated bone cutting capabilities could help reduce procedure-related physical strains for surgeons, they added.
“I wouldn't be surprised if there's some back and forth with the FDA, given that this is new-to-the-world technology,” Tornos said.
Zimmer’s 510(k) is a 90-day submission, and the expected 2027 launch is ahead of the company’s original plans for 2028.